High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy

Area of Science:

• Immunotherapy
• Gene Editing
• Oncology

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy shows promise for blood cancers.
• Random CAR gene integration poses safety risks.
• Precise CAR integration enhances T cell therapy stability and function.

Purpose of the Study:

• To develop a safer and more efficient method for CAR-T cell generation.
• To improve the knock-in efficiency of CAR sequences into specific gene loci.
• To leverage CRISPR/Cpf1 for enhanced homology-directed repair (HDR) in T cells.

Main Methods:

• Utilized CRISPR/Cpf1 gene editing for precise CAR sequence integration.
• Combined electroporation and adeno-associated virus (AAV) delivery.
• Targeted knock-in of CAR cassette into specific gene loci (e.g., TRAC, PDCD1).

Main Results:

• Achieved high efficiency in precise CAR sequence integration.
• Demonstrated superior homology-directed repair (HDR) rate with Cpf1 compared to Cas9.
• Enabled the generation of potentially safer and more potent CAR-T cells.

Conclusions:

• The developed CRISPR/Cpf1 method offers an efficient and precise approach for CAR-T cell engineering.
• This strategy mitigates risks associated with random gene integration.
• The method holds potential for advancing immune cell therapy for hematological malignancies.